Hematology Frontier Archives - Page 101 of 108

Unveiling the Role of BMSCs in NK Cell Exhaustion via the Tim-3/Galectin-9 Pathway in Multiple Myeloma

By Yin, Jiale 2024.02.20

In March 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Clinical And Translational Medicine(IF=10.6). The title of the study…

《Hematology frontier》Wishing all medical colleagues a happy Lunar New Year

By Lisa Cui 2024.02.18

Strategy First! UCLI-ICML Joint Session Lays Foundation for Collaboration

By Mourabit Halima 2024.02.15

Editor's note: From June 13-17, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held in Lugano, Switzerland. As the largest international conference on malignant lymphoma, the event gathered…

Polatuzumab Vedotin Enhances Treatment Efficacy in Previously Untreated DLBCL: Insights from the Asia Subpopulation of the POLARIX Trial

By Yin, Jiale 2024.02.07

In April 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood (IF=25.669). The title of the study is "Polatuzumab…

$Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study$

Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study

By Yin, Jiale 2024.02.07

In August 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood Advances (IF=7.642). The title of the study is "Orelabrutinib for…

$Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study$

Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study

By Yin, Jiale 2024.02.07

In November 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——American Journal of Hematology (IF=12.8). The title of…

$Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma$

Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

By Yin, Jiale 2024.02.07

In September 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Signal Transduction and Targeted Therapy (IF=38.12). The title…

Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications

By Yin, Jiale 2024.02.07

In September 2023, a retrospective multicentric study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Haematologica (IF=11.047). The title of the study…

Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

By Mourabit Halima 2024.01.26

From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology Department at Shanxi Baiqiu'en Hospital, China, had three research results selected for presentation. Oncology Frontier specially invited Dr. Wei to present the findings.

Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes

By Mourabit Halima 2024.01.26

Dr. Komrokji delved into the revised classifications for Myelodysplastic Syndromes (MDS) unveiled at the International Congress. The discussion contrasted the 2016 and 2022 editions, spotlighting new molecularly defined subcategories, such as SF3B1 MDS and biallelic p53, alongside morphological distinctions like MDS with increased blast types, hypoplastic MDS, and MDS with fibrosis. Dr. Komrokji's insights underscored the evolving MDS classification landscape and promising therapeutic frontiers, marking a pivotal advancement in understanding MDS and refining patient care.